



Turning Lead to Gold – Successful Strategies for ALCHEMIST Implementation

Melissa Meredith, MS, CCRP
Washington University School of Medicine

Alliance Spring Meeting, 5-15-2015

Presentation Objectives

- Successfully pre-register and register patients to A151216
 - Finding potential study candidates
 - Identifying the best time to consent
- Efficiently perform all items required by the A151216 protocol
 - Ensuring tissue and blood samples and patient questionnaires are obtained in a timely manner
- Q&A Session

Identifying Patients

- Candidates are identified following surgery at the time of consultation with medical oncology
 - If patient is not adjuvant chemo/RT candidate, consented at consult visit
 - If patient is adjuvant chemo/RT candidate, consented to A151216 halfway through therapy
- All patients with a diagnosis of resected non-squamous NSCLC are screened

Study Procedures

- Blood collection
 - After pre-registration and up to 30 days following registration
 - Changed in recent amendment – was prior to pre-registration
- Baseline clinical information
 - Baseline Data
 - Patient Questionnaires
- Tissue submission

Tissue Submission

- Tissue requested the day of consent
 - Pathology at our site has 10 business day turnaround time
- Tissue block is easiest to send, as patients have a large amount of tissue from resection
- Response Genetics faxes report within 14 business days

Q&A Session

- Questions? Concerns?